Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells.

Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Jun 4. pii: molcanres.0191.2019. doi: 10.1158/1541-7786.MCR-19-0191. [Epub ahead of print]

PMID:
31164413
2.

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ.

J Pancreat Cancer. 2019 May 2;5(1):12-21. doi: 10.1089/pancan.2019.0003. eCollection 2019.

3.

Corrigendum: Metabolic Dependencies in Pancreatic Cancer.

Vaziri-Gohar A, Zarei M, Brody JR, Winter JM.

Front Oncol. 2019 Jan 31;8:672. doi: 10.3389/fonc.2018.00672. eCollection 2018.

4.

Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure.

Bauer TM, Dhir T, Strickland A, Thomsett H, Goetz AB, Cannaday S, Brody JR, Pishvaian MJ, Yeo CJ.

J Pancreat Cancer. 2018 Nov 1;4(1):81-87. doi: 10.1089/pancan.2018.0015. eCollection 2018. Review.

5.

Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry.

Yeo TP, Lavu H, Nevler A, Brumbaugh J, Vicchairelli D, Winter JM, Brody JR, Yeo CJ.

J Pancreat Cancer. 2018 Jun 1;4(1):17-24. doi: 10.1089/pancan.2018.0004. eCollection 2018.

6.

Metabolic Dependencies in Pancreatic Cancer.

Vaziri-Gohar A, Zarei M, Brody JR, Winter JM.

Front Oncol. 2018 Dec 12;8:617. doi: 10.3389/fonc.2018.00617. eCollection 2018. Review. Erratum in: Front Oncol. 2019 Jan 31;8:672.

7.

Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets.

Jain A, Brown SZ, Thomsett HL, Londin E, Brody JR.

Methods Mol Biol. 2019;1882:239-252. doi: 10.1007/978-1-4939-8879-2_22. Review.

PMID:
30378060
8.

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR.

Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.

PMID:
30266763
9.

RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.

Zarei M, Lal S, Vaziri-Gohar A, O'Hayer K, Gunda V, Singh PK, Brody JR, Winter JM.

Mol Cancer Res. 2019 Feb;17(2):508-520. doi: 10.1158/1541-7786.MCR-18-0557. Epub 2018 Sep 28.

PMID:
30266754
10.

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, Baker TM, Marshall JL, Isaacs C.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00286. Epub 2018 Jul 23.

11.

RNA binding protein HuR regulates extracellular matrix gene expression and pH homeostasis independent of controlling HIF-1α signaling in nucleus pulposus cells.

Pan H, Strickland A, Madhu V, Johnson ZI, Chand SN, Brody JR, Fertala A, Zheng Z, Shapiro IM, Risbud MV.

Matrix Biol. 2019 Apr;77:23-40. doi: 10.1016/j.matbio.2018.08.003. Epub 2018 Aug 7.

PMID:
30092282
12.

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF 3rd.

Clin Cancer Res. 2018 Oct 15;24(20):5018-5027. doi: 10.1158/1078-0432.CCR-18-0531. Epub 2018 Jun 28.

PMID:
29954777
13.

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, Palmaira RLD, Javed AA, Huynh JC, Johnson M, Arora K, Robine N, Shah M, Sanghvi R, Goetz AB, Lowder CY, Martello L, Driehuis E, LeComte N, Askan G, Iacobuzio-Donahue CA, Clevers H, Wood LD, Hruban RH, Thompson E, Aguirre AJ, Wolpin BM, Sasson A, Kim J, Wu M, Bucobo JC, Allen P, Sejpal DV, Nealon W, Sullivan JD, Winter JM, Gimotty PA, Grem JL, DiMaio DJ, Buscaglia JM, Grandgenett PM, Brody JR, Hollingsworth MA, O'Kane GM, Notta F, Kim E, Crawford JM, Devoe C, Ocean A, Wolfgang CL, Yu KH, Li E, Vakoc CR, Hubert B, Fischer SE, Wilson JM, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson DA.

Cancer Discov. 2018 Sep;8(9):1112-1129. doi: 10.1158/2159-8290.CD-18-0349. Epub 2018 May 31.

PMID:
29853643
14.

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR.

Cancer. 2018 Jun 1;124(11):2337-2346. doi: 10.1002/cncr.31309. Epub 2018 Mar 26.

15.

STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.

Maranto C, Udhane V, Hoang DT, Gu L, Alexeev V, Malas K, Cardenas K, Brody JR, Rodeck U, Bergom C, Iczkowski KA, Jacobsohn K, See W, Schmitt SM, Nevalainen MT.

Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. doi: 10.1158/1078-0432.CCR-17-2768. Epub 2018 Feb 26.

16.

Complex HuR function in pancreatic cancer cells.

Brody JR, Dixon DA.

Wiley Interdiscip Rev RNA. 2018 May;9(3):e1469. doi: 10.1002/wrna.1469. Epub 2018 Feb 16. Review.

17.

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2.

Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR.

J Am Coll Surg. 2018 Apr;226(4):596-603. doi: 10.1016/j.jamcollsurg.2017.12.052. Epub 2018 Feb 7.

18.

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative.

Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S, Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E 3rd, Brody JR.

Oncotarget. 2016 Nov 8;8(48):83446-83456. doi: 10.18632/oncotarget.13225. eCollection 2017 Oct 13.

19.

Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.

Peng W, Furuuchi N, Aslanukova L, Huang YH, Brown SZ, Jiang W, Addya S, Vishwakarma V, Peters E, Brody JR, Dixon DA, Sawicki JA.

Mol Cell Biol. 2018 Jan 16;38(3). pii: e00427-17. doi: 10.1128/MCB.00427-17. Print 2018 Feb 1.

20.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

21.

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM.

Cancer Res. 2017 Aug 15;77(16):4460-4471. doi: 10.1158/0008-5472.CAN-17-0015. Epub 2017 Jun 26.

22.

Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.

Pishvaian MJ, Brody JR.

Oncology (Williston Park). 2017 Mar 15;31(3):159-66, 168. Review.

23.

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.

Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.

Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.

24.

CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.

Lal S, Cheung EC, Zarei M, Preet R, Chand SN, Mambelli-Lisboa NC, Romeo C, Stout MC, Londin E, Goetz A, Lowder CY, Nevler A, Yeo CJ, Campbell PM, Winter JM, Dixon DA, Brody JR.

Mol Cancer Res. 2017 Jun;15(6):696-707. doi: 10.1158/1541-7786.MCR-16-0361. Epub 2017 Feb 27.

25.

Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas.

Jinawath N, Shiao MS, Norris A, Murphy K, Klein AP, Yonescu R, Iacobuzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody JR, Griffin CA, Harada S.

Genes Chromosomes Cancer. 2017 May;56(5):427-435. doi: 10.1002/gcc.22447. Epub 2017 Mar 7.

PMID:
28124395
26.

Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.

Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR.

Ann Surg. 2018 Feb;267(2):364-369. doi: 10.1097/SLA.0000000000002088.

PMID:
27893535
27.

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.

Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S.

Oncotarget. 2017 Jun 6;8(23):37923-37934. doi: 10.18632/oncotarget.13544. Review.

28.

Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.

Blanco FF, Preet R, Aguado A, Vishwakarma V, Stevens LE, Vyas A, Padhye S, Xu L, Weir SJ, Anant S, Meisner-Kober N, Brody JR, Dixon DA.

Oncotarget. 2016 Nov 8;7(45):74043-74058. doi: 10.18632/oncotarget.12189.

29.

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner.

Lal S, Zarei M, Chand SN, Dylgjeri E, Mambelli-Lisboa NC, Pishvaian MJ, Yeo CJ, Winter JM, Brody JR.

Sci Rep. 2016 Sep 12;6:33323. doi: 10.1038/srep33323.

30.

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM.

Cancer Biol Ther. 2018 Apr 3;19(4):249-253. doi: 10.1080/15384047.2016.1210743. Epub 2018 Mar 6.

31.

GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.

Zhou H, Telonis AG, Jing Y, Xia NL, Biederman L, Jimbo M, Blanco F, Londin E, Brody JR, Rigoutsos I.

Cell Death Dis. 2016 Jul 14;7:e2294. doi: 10.1038/cddis.2016.169.

32.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

33.

Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?

O'Hayer KM, Brody JR.

Discov Med. 2016 Feb;21(114):117-23. Review.

34.

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.

Huang YH, Peng W, Furuuchi N, DuHadaway JB, Jimbo M, Pirritano A, Dunton CJ, Daum GS, Leiby BE, Brody JR, Sawicki JA.

Oncotarget. 2016 Apr 19;7(16):21812-24. doi: 10.18632/oncotarget.7840.

35.

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms.

Chand S, O'Hayer K, Blanco FF, Winter JM, Brody JR.

Int J Biol Sci. 2016 Jan 27;12(3):273-82. doi: 10.7150/ijbs.14951. eCollection 2016. Review.

36.

Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.

Huang YH, Peng W, Furuuchi N, Gerhart J, Rhodes K, Mukherjee N, Jimbo M, Gonye GE, Brody JR, Getts RC, Sawicki JA.

Cancer Res. 2016 Mar 15;76(6):1549-59. doi: 10.1158/0008-5472.CAN-15-2073. Epub 2016 Feb 26. Erratum in: Cancer Res. 2016 Jun 1;76(11):3437.

37.

Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.

Weinberg BA, Yabar CS, Brody JR, Pishvaian MJ.

Oncology (Williston Park). 2015 Nov;29(11):809-20, 886. Review.

38.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
39.

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK.

Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15. Review.

40.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

41.

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.

Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES.

Oncotarget. 2015 Jun 30;6(18):15788-801.

42.

Novel targets in pancreatic cancer research.

Kozak G, Blanco FF, Brody JR.

Semin Oncol. 2015 Feb;42(1):177-87. doi: 10.1053/j.seminoncol.2014.12.015. Epub 2014 Dec 10. Review.

PMID:
25726061
43.

Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs.

Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I.

Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1106-15. doi: 10.1073/pnas.1420955112. Epub 2015 Feb 23.

44.

Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays.

Cozzitorto JA, Jimbo M, Chand S, Blanco F, Lal S, Gilbert M, Winter JM, Gorospe M, Brody JR.

Methods Mol Biol. 2015;1262:239-46. doi: 10.1007/978-1-4939-2253-6_14.

PMID:
25555585
45.

Upgrading gemcitabine with recycled kinase inhibitors.

Blanco FF, Pishvaian MJ, Brody JR.

Cell Cycle. 2014;13(18):2810-1. doi: 10.4161/15384101.2014.954211. No abstract available.

46.

PARP inhibitors for chemoprevention--letter.

Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR.

Cancer Prev Res (Phila). 2014 Nov;7(11):1170-1. doi: 10.1158/1940-6207.CAPR-14-0220. No abstract available.

47.

MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.

Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM.

Mol Cancer Res. 2015 Mar;13(3):439-48. doi: 10.1158/1541-7786.MCR-14-0199. Epub 2014 Oct 21.

48.

Fusing transcriptomics to progressive prostate cancer.

Jimbo M, Knudsen KE, Brody JR.

Am J Pathol. 2014 Oct;184(10):2608-10. doi: 10.1016/j.ajpath.2014.08.001. Epub 2014 Aug 14.

PMID:
25128905
49.

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.

Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11.

50.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

Supplemental Content

Loading ...
Support Center